Humanigen Inc

NASDAQ:HGEN   3:59:58 PM EDT
9.46
-0.08 (-0.84%)
Products, Earnings Announcements

Humanigen Reports Third Quarter And Nine Months Ended September 30, 2020 Financial Results

Published: 11/11/2020 12:14 GMT
Humanigen Inc (HGEN) - Humanigen Reports Third Quarter and Nine Months Ended September 30, 2020 Financial Results.
Q3 Loss per Share $0.71.
Q3 Earnings per Share Estimate $-0.57 -- Refinitiv Ibes Data (analyst estimates).
Expect Expenses to Continue to Increase Significantly in Remaining Three Months of 2020.
As of September 30, 2020, Co Had Cash and Cash Equivalents of $91.4 Million.
Research and Development Expense May Double As We Expand Phase 3 Clinical Study and Continue Production of Lenzilumab in Q4 2020.
Current Cash Balance is Sufficient to Complete Phase 3 Trial and File Eua.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.63

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.39

More details on our Analysts Page.